Search

• New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)

  Media

  Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death1.

  https://www.gsk.com/en-gb/media/press-releases/new-long-term-organ-damage-analysis-published-for-gsk-s-benlysta-belimumab/

  First published: 03 March 2016

• ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

  Media

  Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/

  First published: 24 July 2018

• Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype

  Media

  Mepolizumab is the first targeted IL-5 biologic available in China as an add-on maintenance treatment for severe eosinophilic asthma.

  https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype/

  First published: 10 January 2024

• GSK and Theravance announce start of phase III lung function study with ‘closed’ triple combination treatment FF/UMEC/VI for COPD

  Media

  GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-start-of-phase-iii-lung-function-study-with-closed-triple-combination-treatment-ffumecvi-for-copd/

  First published: 09 February 2015

• GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties

  Media

  GSK announced an agreement with Novartis Pharma to divest its rights in ofatumumab for auto-immune indications, incl. multiple sclerosis.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-ofatumumab-for-auto-immune-indications-to-novartis-for-up-to-1-billion-plus-royalties/

  First published: 21 August 2015

• GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension

  Media

  GSK today announced publication of first-line combination therapy of ambrisentan and tadalafil in treatment-naïve patients with PAH.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-phase-3b4-study-of-ambrisentan-and-tadalafil-as-first-line-combination-treatment-in-patients-with-pulmonary-arterial-hypertension/

  First published: 26 August 2015

• Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems

  Media

  A five-year partnership to fight malaria and improve health in five countries has today been launched by Comic Relief and GSK.

  https://www.gsk.com/en-gb/media/press-releases/comic-relief-and-gsk-form-five-year-partnership-to-fight-malaria-and-strengthen-health-systems/

  First published: 15 December 2015

• GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

  Media

  GSK announced completion of its divesting of rights to ofatumumab for auto-immune indications to Novartis Pharma following reg. approval.

  https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/

  First published: 21 December 2015

• GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma

  Media

  GSK announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) met its primary endpoint of PFS

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-results-for-phase-iii-study-of-the-combination-of-tafinlar-dabrafenib-and-mekinist-trametinib-in-metastatic-melanoma/

  First published: 24 January 2014

• GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth

  Media

  GSK today announced a series of investments in sub-Saharan Africa designed to address pressing needs and contribute to long-term growth.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-strategic-investments-in-africa-to-increase-access-to-medicines-build-capacity-and-deliver-sustainable-growth/

  First published: 31 March 2014